A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)

NCT01046110 Phase 3 COMPLETED Results posted

This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	COMPLETED
Enrolment	458
Start date	2010-01
Completion	2010-11

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Interventions

• insulin degludec
• sitagliptin

Primary outcomes

• Change in Glycosylated Haemoglobin (HbA1c) — Week 0, Week 26
  Change from baseline in HbA1c after 26 weeks of treatment

Countries

United States, Argentina, Canada, India, Mexico, South Africa, Turkey (Türkiye)